Journal article
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
Abstract
BACKGROUND: In the Gynecologic Cancer Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuation treatment for 18 cycles. In a preliminary analysis of a high-risk subset of patients, there was also an improvement in overall survival. This study aims to describe …
Authors
Stark D; Nankivell M; Pujade-Lauraine E; Kristensen G; Elit L; Stockler M; Hilpert F; Cervantes A; Brown J; Lanceley A
Journal
The Lancet Oncology, Vol. 14, No. 3, pp. 236–243
Publisher
Elsevier
Publication Date
3 2013
DOI
10.1016/s1470-2045(12)70567-3
ISSN
1470-2045